1. What Is SNAC? Chemistry, Function & Role in Oral Drug Delivery

SNAC -- Sodium N-[8-(2-Hydroxybenzoyl)Amino] Caprylate -- is a synthetic pharmaceutical excipient classified as an intestinal permeation enhancer. Its chemical name is sodium 8-[(2-hydroxybenzoyl)amino]octanoate, with CAS number 203787-91-1 and molecular formula C15H2₀NNaO4. It is also known by its USAN name Salcaprozate Sodium.

SNAC was developed specifically to solve one of pharmaceutical science's most persistent problems: the oral bioavailability of peptide drugs. Peptides like semaglutide are large molecules that are enzymatically degraded in the gastrointestinal tract and poorly absorbed across the intestinal membrane. Without an absorption enhancer, they must be delivered by injection.

How SNAC Works: The Mechanism

When co-administered with a peptide drug in a tablet formulation, SNAC creates a localised, temporary microenvironment of elevated pH around the drug molecule in the gastric mucosa. This pH buffering effect serves two functions simultaneously:

2. Why SNAC Demand Is Surging in 2025-2026: The GLP-1 Catalyst

The trajectory of SNAC demand is inseparably linked to the global GLP-1 receptor agonist market -- one of the fastest-growing pharmaceutical categories in history. Global GLP-1 sales were estimated at $65.8 billion in 2025 and are forecast to reach $324.5 billion by 2035, growing at a CAGR of 17.3% (FactMR, 2025).

Within this market, the shift from injectable to oral GLP-1 formulations is the defining trend of 2025-2026, and SNAC is the excipient that makes it possible.

The December 2025 Inflection Point

The Wegovy® pill's FDA approval is the single most significant demand catalyst for SNAC since Rybelsus® launched in 2019. Obesity treatment represents a vastly larger patient population than type 2 diabetes alone -- Novo Nordisk has stated confidence in its ability to supply the market, and the demand trajectory for oral semaglutide is expected to significantly exceed all pre-2026 SNAC market forecasts.

Additionally, Novo Nordisk has agreed with the US Administration to lower semaglutide prices across Medicare and Medicaid from 2026, with a three-year tariff exemption -- a policy development that will meaningfully expand the US patient population accessing oral semaglutide and, by extension, SNAC demand.

3. Global Market Size & Forecast 2025-2035

Market sizing for SNAC varies across research providers depending on scope -- whether measuring the pure pharmaceutical excipient, the broader salcaprozate sodium ingredient market, or the end-market GLP-1 supply chain. The table below provides a consolidated view of key forecasts:

4. Global CapEx Wave: Who Is Investing and How Much

The SNAC and GLP-1 manufacturing expansion story is one of the most significant pharmaceutical CapEx cycles in recent history. Billions of dollars are flowing into peptide manufacturing infrastructure globally -- investments that will determine the future supply, pricing, and geographic distribution of SNAC production capacity.

The CordenPharma Expansion in Detail

CordenPharma's €900M commitment -- the largest single strategic investment in the company's history -- is the most directly SNAC-relevant CapEx programme. The expansion covers three parallel workstreams: expanding large-scale peptide synthesis capacity at its Colorado, US site (already partially operational and manufacturing under long-term contracts totalling ~€3Bn); constructing a new greenfield peptide manufacturing site in Europe (located in Frankfurt, Germany); and building a new peptide R&D and development facility in Switzerland.

5. Global Supplier Landscape: China, India & Western Producers

SNAC is not a widely manufactured commodity. It is a specialised synthetic excipient requiring dedicated chemistry expertise and strict GMP compliance. The global supplier base is currently concentrated, with China dominating current production and India and Western manufacturers expanding capacity.

Supplier Selection Criteria for SNAC

Given SNAC's role as a critical pharmaceutical excipient destined for human oral drug products, supplier qualification must be rigorous. Procurement teams should evaluate suppliers against the following key criteria:

6. SNAC & High-Cost Region Markets: What Patients and Payers Should Know

For patients and procurement professionals operating in High Cost Regions (HCR) -- the US, EU, UK, Japan, and Australia -- the SNAC supply chain story is fundamentally a positive one for access and affordability, despite the short-term complexity of a rapidly scaling market.

Better Access, Not Higher Cost

The oral GLP-1 format enabled by SNAC removes significant access barriers compared to weekly self-injection therapy. No cold chain requirement. No injection training or anxiety. No pharmacy refrigeration. This translates directly into higher patient adherence and a larger treatable population -- particularly for patients in HCR markets who previously declined injectable therapy.

Pricing Policy Is Moving in the Right Direction

In November 2025, Novo Nordisk agreed with the US Administration to lower semaglutide prices for Medicare Part D and Medicaid from 2026, with a three-year tariff exemption on semaglutide medicines. This agreement is explicitly designed to expand access for the most cost-sensitive US patient populations -- and represents a meaningful counterweight to any excipient supply cost pressures.

The Long-Term Trajectory: Biosimilars and Scale

First semaglutide patent expirations will trigger a wave of oral generic and biosimilar entrants -- all of which will require SNAC. This biosimilar pipeline creates a second, larger wave of SNAC demand while simultaneously driving competitive price pressure on the finished drug. The net effect for HCR patients: greater choice, improved access, and lower out-of-pocket costs over time.

7. Five Demand Drivers That Will Shape SNAC Through 2030

8. Strategic Procurement Guide: How to Source SNAC in 2026

SNAC procurement in 2026 requires a more strategic approach than standard excipient sourcing. With demand accelerating, supply concentrated in China, and regulatory requirements stringent for pharmaceutical-grade material, procurement teams need to act proactively rather than reactively.

Step 1 -- Map Your Exposure

Identify whether SNAC is a current or planned component of your formulation pipeline. For generic pharmaceutical manufacturers entering oral semaglutide or future oral peptide development, establish SNAC sourcing as a critical path item -- not a late-stage procurement decision.

Step 2 -- Qualify Multiple Suppliers Across Geographies

Over-reliance on a single Chinese supplier creates concentration risk -- both geopolitical (US-China trade dynamics affect APIs and excipients) and operational (capacity constraints in a tightening market). Qualify at least one China supplier, one India supplier, and one European/US supplier as part of your approved vendor list. All three geographies have FDA-DMF-capable SNAC manufacturers.

Step 3 -- Demand Full Documentation at Qualification

For US-market pharmaceutical products, SNAC documentation requirements are non-negotiable: CoA per batch, CoO, SDS, TDS, stability data, GMP certification, and DMF reference number. Validate the DMF status directly with the supplier -- not just from their marketing materials.

Step 4 -- Negotiate Supply Security, Not Just Price

In a seller's market with accelerating demand, price-only negotiation is insufficient. Structure supplier agreements to include: minimum allocation commitments, lead time guarantees, advance purchase provisions for capacity-constrained periods, and quality escalation clauses. Consider 12-24 month blanket orders with rolling delivery schedules.

Step 5 -- Monitor the Biosimilar and Policy Landscape

SNAC procurement strategy should be reviewed at least quarterly through 2027. Monitor patent expiry timelines for semaglutide in key markets, regulatory approvals for new oral peptide products, and any changes to US drug pricing or tariff policy affecting GLP-1 supply chains.

9. How APAC Supply Chain Supports SNAC Procurement

At APAC Supply Chain | CDMO, we work with pharmaceutical manufacturers, R&D procurement teams, and formulation specialists across India, Southeast Asia, the Middle East, and High Cost Region markets including the US and EU. Our role in SNAC procurement is to bring category expertise, verified supplier access, and documentation integrity to a complex and rapidly evolving excipient market.

10. Frequently Asked Questions

11. Conclusion

SNAC -- Sodium N-[8-(2-Hydroxybenzoyl)Amino] Caprylate -- is among the most consequential pharmaceutical excipients of this decade. Its role as the enabler of oral peptide drug delivery, and specifically its position as the sole absorption-enhancing excipient in Rybelsus® and the FDA-approved Wegovy® pill, places it at the intersection of two of the most powerful forces in modern healthcare: the GLP-1 revolution and the global shift toward patient-friendly oral biologics.

The market fundamentals are compelling: $15.2M to $30.7M in excipient-specific market growth, a broader GLP-1 manufacturing ecosystem approaching $22 billion by 2030, over €900M in committed CapEx from CDMO leaders, and a demand catalyst -- the Wegovy® pill US launch -- that was not fully priced into any pre-2026 forecast. For procurement and supply chain professionals, the message is clear: SNAC deserves to be treated as a strategic material, sourced with the same rigour and multi-supplier discipline as a primary API.

The window to build a resilient, multi-sourced SNAC supply chain at today's market conditions is open right now. The companies that act in 2026 will be better positioned for the biosimilar wave, the next generation of oral peptide therapies, and the inevitable tightening of SNAC supply as global demand accelerates.